BioTime Investigating (BTIM) Stem Cells To Treat Cancer

By: China Bio Today Thursday, October 22, 2009 2:42 PM

Article Author

Follow Me

Bio and Articles
Author's Website

Vote for next session

The next market session will close:

BioTime, Inc. (OTCBB: BTIM) announced that Dr. David Jin, Chief Medical Officer of BioTime's newly formed subsidiary, OncoCyte Corporation, will present the keynote address at the Fifth Chinese Congress on Stem Cell Therapy in Beijing. The presentation, which will be delivered Friday, October 23, will discuss OncoCyte's technology that uses hemangiogenic stem cell technology to target and destroy tumors.

The presentation is entitled "Chemokine regulation of hematopoietic stem cell mobilization and angiogenesis." OncoCyte intends to use human embryonic stem cell technology to create genetically modified stem cells capable of targeting specific malignant tumors while carrying genes that destroy cancer cells.

OncoCyte's plan is radically different from most proposed uses of stem cells, which are generally aimed at regenerating tissue.

BioTime announced the formation of OncoCyte last week. BioTime licensed its cell-based cancer therapy technology, including early patent filings on using stem cells to target malignant tumors, to the new subsidiary. OncoCyte also said a private investor provided start-up capital, paying $2 million for 3,000,000 shares of the company, a 15% stake. The investor has the option of purchasing another 3,000,000 shares, also for $2 million, on or before April 15, 2010. The company and the investor placed a market value on OncoCyte's technology at about $15 million.

Last month, BioTime announced that it has established a China subsidiary, BioTime Asia, which is tasked with marketing the company's stem cell products in China and throughout Asia. BioTime will also seek to develop stem cell therapies in China that are aimed at treating a number of diseases, including the cancer research. BioTime hired Dr. Lu Daopei, a prominent China hematologist, to help set up and manage the clinical trials of its therapeutic stem cell products.

In addition to cancer, BioTime plans to develop therapeutic stem cell products in China for the treatment of ophthalmologic, skin, musculo-skeletal system and hematologic diseases. At present, BioTime's lead product is Hextend®, a blood plasma volume expander.

Bookmark:
Email
Print


10/26/2009 8:32:30 AM Stem Cell Updates by Ray Mumme Hello, Very interesting article, it is here now. I would like to introduce you to the World’s First Stem Cell Enhancer. It is proved by Science and Medical Teams in a Peer Review study. www.adultstemcellsrelease.com . Adult stem Cells can become any organ, tissue, or muscle in the body. After taking 1 gram of StemEnhance your body releases 3 to 4 million adult stem cells, into the blood stream. This is the body’s natural way to renew, refresh, and rejuvenate itself. We are unleashing a whole new system of the body that has always been there. This is an all natural botanical extract for everyone. www.rmumme.stemtechbiz.com Ray Mumme raymumme@gmail.com 314-488-4454 Reply Rating: (0) (0)

Hello,
Very interesting article, it is here now. I would like to introduce you to the World’s First Stem Cell Enhancer. It is proved by Science and Medical Teams in a Peer Review study. www.adultstemcellsrelease.com . Adult stem Cells can become any organ, tissue, or muscle in the body. After taking 1 gram of StemEnhance your body releases 3 to 4 million adult stem cells, into the blood stream. This is the body’s natural way to renew, refresh, and rejuvenate itself. We are unleashing a whole new system of the body that has always been there. This is an all natural botanical extract for everyone.
www.rmumme.stemtechbiz.com
Ray Mumme
raymumme@gmail.com
314-488-4454

Rating: (0) (0)

Post Comment

Name:

Alert for new comments:

Your email:

Your Website:

Title:

Comments:

The above story is the opinion of the author only and it does not reflect iStockAnalyst opinion. Further, the author is not personally advising you regarding the suitability of the story for your investment needs. In no event iStockAnalyst will be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from or arising out of, or in connection with the use of this information. Please consult your investment advisor before making any investment decision.

Related Stories